Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling
Advanced Materials · 2024-05 · 36 (19)
DOI: 10.1002/adma.202308377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 22.02.2024. Verfasst von Skylar T Chuang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, 123 Bevier Road, Piscataway, NJ, 08854, USA. Hauptthemen laut MEDLINE: Efferocytosis, Liver X Receptors, Macrophages, Reactive Oxygen Species. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
The removal of dying cells, or efferocytosis, is an indispensable part of resolving inflammation. However, the inflammatory microenvironment of the atherosclerotic plaque frequently affects the biology of both apoptotic cells and resident phagocytes, rendering efferocytosis dysfunctional. To overcome this problem, a chimeric antigen receptor (CAR) macrophage that can target and engulf phagocytosis‐resistant apoptotic cells expressing CD47 is developed. In both normal and inflammatory circumstances, CAR macrophages exhibit activity equivalent to antibody blockage. The surface of CAR macrophages is modified with reactive oxygen species (ROS)‐responsive therapeutic nanoparticles targeting the liver X receptor pathway to improve their cell effector activities. The combination of CAR and nanoparticle engineering activated lipid efflux pumps enhances cell debris clearance and reduces inflammation. It is further suggested that the undifferentiated CAR‐Ms can transmigrate within a mico‐fabricated vessel system. It is also shown that our CAR macrophage can act as a chimeric switch receptor (CSR) to withstand the immunosuppressive inflammatory environment. The developed platform has the potential to contribute to the advancement of next‐generation cardiovascular disease therapies and further studies include in vivo experiments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, 123 Bevier Road, Piscataway, NJ, 08854, USA.
ORCID-Profile: Ki-Bum Lee
Förderung
- NIH HHS
- NHLBI NIH HHS
- NIEHS NIH HHS
- NIAMS NIH HHS
- Alzheimer's Association
- NINDS NIH HHS
- NIBIB NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Chuang, S. T., Stein, J. B., Nevins, S., Kilic Bektas, C., Choi, H. K., Ko, W. K., Jang, H., Ha, J., & Lee, K. B. (2024). Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling. Advanced Materials, 36(19). https://doi.org/10.1002/adma.202308377
Vancouver
Chuang ST, Stein JB, Nevins S, Kilic Bektas C, Choi HK, Ko WK, et al. Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling. Advanced Materials. 2024;36(19). doi:10.1002/adma.202308377
BibTeX
@article{Chuang2024,
author = {Chuang, Skylar T and Stein, Joshua B and Nevins, Sarah and Kilic Bektas, Cemile and Choi, Hye Kyu and Ko, Wan-Kyu and Jang, Hyunjun and Ha, Jihun and Lee, Ki-Bum},
title = {Enhancing CAR Macrophage Efferocytosis Via Surface Engineered Lipid Nanoparticles Targeting LXR Signaling},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {19},
doi = {10.1002/adma.202308377}
}
EUVIMED